DDInter667 DDInter782
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Erlotinib {u} (Compound) resembles {v} (Compound) Vandetanib
Erlotinib {u} (Compound) resembles {v} (Compound) Gefitinib
Erlotinib {u} (Compound) treats {v} (Disease) kidney cancer
Erlotinib {u} (Compound) binds {v} (Gene) CYP1A2
Erlotinib {u} (Compound) upregulates {v} (Gene) IL1B
Erlotinib {u} (Compound) downregulates {v} (Gene) COX8A
Erlotinib {u} (Compound) causes {v} (Side Effect) Drug interaction
Erlotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cobicistat
Erlotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cimetidine
Erlotinib (Compound) resembles Vandetanib (Compound)
Erlotinib (Compound) resembles Gefitinib (Compound)
Erlotinib (Compound) treats kidney cancer (Disease)
Erlotinib (Compound) binds CYP1A2 (Gene)
Erlotinib (Compound) upregulates IL1B (Gene)
Erlotinib (Compound) downregulates COX8A (Gene)
Erlotinib (Compound) causes Drug interaction (Side Effect)
Erlotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine